mhurhangee/patent-ind-claim-en huggingface dataset:
The use as fragrance of a compound of formula (I) wherein n is 1 or 2; R 1 and R 2 are independently selected from hydrogen, methyl, ethyl, and C 3 - C 5 alkyl; or R 1 and R 2 form together with the carbon atom to which they are attached C 3 - C 6 cycloalkyl; or R 1 and R 2 form together methylidene; R 3 is selected from hydrogen, and C 1 - C 3 alkyl; R 4 is selected from hydrogen, and C 1 - C 3 alkyl; and X is -CN; or X is -C(O)OR 5 , wherein R 5 is selected from methyl, ethyl, C 3 - C 5 alkyl, vinyl and C 3 - C 5 alkenyl; with the proviso that a) at least two of the residues R 1 , R 2 and R 3 are not hydrogen; b) when R 3 is hydrogen, R 4 is selected from C 1 - C 3 alkyl; c) when X is -CN, and R 1 , R 2 and R 3 are methyl, then R 4 is not hydrogen. n is 1 or 2; R 1 and R 2 are independently selected from hydrogen, methyl, ethyl, and C 3 - C 5 alkyl; or R 1 and R 2 form together with the carbon atom to which they are attached C 3 - C 6 cycloalkyl; or R 1 and R 2 form together methylidene; R 3 is selected from hydrogen, and C 1 - C 3 alkyl; R 4 is selected from hydrogen, and C 1 - C 3 alkyl; and X is -CN; or X is -C(O)OR 5 , wherein R 5 is selected from methyl, ethyl, C 3 - C 5 alkyl, vinyl and C 3 - C 5 alkenyl; with the proviso that a) at least two of the residues R 1 , R 2 and R 3 are not hydrogen; b) when R 3 is hydrogen, R 4 is selected from C 1 - C 3 alkyl; c) when X is -CN, and R 1 , R 2 and R 3 are methyl, then R 4 is not hydrogen. a) at least two of the residues R 1 , R 2 and R 3 are not hydrogen; b) when R 3 is hydrogen, R 4 is selected from C 1 - C 3 alkyl; c) when X is -CN, and R 1 , R 2 and R 3 are methyl, then R 4 is not hydrogen.
A transparent organic light emitting display device comprising: a circuit device layer on a first substrate ; an emission device layer on the circuit device layer; an encapsulation layer on the emission device layer; a second substrate on the encapsulation layer; and a wavelength change layer on the first substrate or the second substrate, characterised in that the wavelength change layer is configured to enable external light to be transmitted in a transparent state being a state that does not exhibit an apparent colour change in transmitted light; wherein: the circuit device layer or the emission device layer comprises an organic material that changes the external light to a yellowish state, and wherein the wavelength change layer comprises a light-absorbing material only absorbing light in a yellowish wavelength range of 500 nm to 680 nm. a circuit device layer on a first substrate ; an emission device layer on the circuit device layer; an encapsulation layer on the emission device layer; a second substrate on the encapsulation layer; and a wavelength change layer on the first substrate or the second substrate, characterised in that the wavelength change layer is configured to enable external light to be transmitted in a transparent state being a state that does not exhibit an apparent colour change in transmitted light; wherein: the circuit device layer or the emission device layer comprises an organic material that changes the external light to a yellowish state, and wherein the wavelength change layer comprises a light-absorbing material only absorbing light in a yellowish wavelength range of 500 nm to 680 nm. the circuit device layer or the emission device layer comprises an organic material that changes the external light to a yellowish state, and wherein the wavelength change layer comprises a light-absorbing material only absorbing light in a yellowish wavelength range of 500 nm to 680 nm.
A method of screening a vaccine for activity, assessing efficacy of a vaccine or predicting in vivo efficacy of a vaccine, comprising: (a) adding a vaccine and one or more cellular activator to a first in vitro cell culture comprising cord blood CD4+ T cells and maintaining the cell culture under conditions promoting development of vaccine-specific T follicular helper (T FH ) cells, (b) forming a second in vitro cell culture comprising T FH cells developed in (a) and cord blood B cells, (c) adding a vaccine-specific antigen to the cell culture of (b) and maintaining the culture under conditions promoting a cellular response, and (d) analyzing supernatant and/or cells from the cell culture of (c) for a cellular response, thereby screening a vaccine for activity, thereby assessing efficacy of a vaccine or wherein when a cellular response is found the vaccine is predicted to have in vivo efficacy, wherein the one or more cellular activator is selected from the group consisting of an anti-CD28 antibody, IL-2, IL-6, IL-12, IL-21, and IL-23; and wherein the cellular response is one or more of production of a cytokine by the B cells, expression of a marker by the B cells, and production of an antibody with binding specificity for the vaccine-specific antigen by the B cells. (a) adding a vaccine and one or more cellular activator to a first in vitro cell culture comprising cord blood CD4+ T cells and maintaining the cell culture under conditions promoting development of vaccine-specific T follicular helper (T FH ) cells, (b) forming a second in vitro cell culture comprising T FH cells developed in (a) and cord blood B cells, (c) adding a vaccine-specific antigen to the cell culture of (b) and maintaining the culture under conditions promoting a cellular response, and (d) analyzing supernatant and/or cells from the cell culture of (c) for a cellular response, thereby screening a vaccine for activity, thereby assessing efficacy of a vaccine or wherein when a cellular response is found the vaccine is predicted to have in vivo efficacy, wherein the one or more cellular activator is selected from the group consisting of an anti-CD28 antibody, IL-2, IL-6, IL-12, IL-21, and IL-23; and wherein the cellular response is one or more of production of a cytokine by the B cells, expression of a marker by the B cells, and production of an antibody with binding specificity for the vaccine-specific antigen by the B cells.
A method for joining rotor blade segments of a rotor blade , the method comprising: forming a female structural member having a receipt portion , a structural portion and a divider bulkhead , the receipt portion defining a cavity , the divider bulkhead being positioned between the receipt portion and the structural portion of the female structural member ; securing the female structural member within a first blade segment ; forming a male structural member having a protrusion portion and a structural portion ; securing the structural portion of the male structural member within a second blade segment ; inserting the protrusion portion of the male structural member into the cavity of the female structural member , wherein, when inserted, an interface of the protrusion portion of the male structural member and the cavity of the female structural member forms one or more internal channels ; and, injecting adhesive from an exterior location of the rotor blade through the divider bulkhead 70 of the female structural member and into the one or more internal channels so as to secure the first and second blade segments together. forming a female structural member having a receipt portion , a structural portion and a divider bulkhead , the receipt portion defining a cavity , the divider bulkhead being positioned between the receipt portion and the structural portion of the female structural member ; securing the female structural member within a first blade segment ; forming a male structural member having a protrusion portion and a structural portion ; securing the structural portion of the male structural member within a second blade segment ; inserting the protrusion portion of the male structural member into the cavity of the female structural member , wherein, when inserted, an interface of the protrusion portion of the male structural member and the cavity of the female structural member forms one or more internal channels ; and, injecting adhesive from an exterior location of the rotor blade through the divider bulkhead 70 of the female structural member and into the one or more internal channels so as to secure the first and second blade segments together.
A process for producing blends made of polylactides (PLAs) and of thermoplastic polyurethanes (TPUs), via A) reaction of at least one thermoplastic polyurethane with at least one diisocyanate or one isocyanate prepolymer which has at least two isocyanate groups, or a mixture thereof, in the melt, with reduction of the molar mass of the thermoplastic polyurethane and with formation of a thermoplastic polyurethane having an excess of isocyanate end groups, B) introduction of at least one polylactide into the melt of the stage A) product, and reaction of the stage A) product with the polylactide at a temperature below 190°C, where the proportion of the polylactide in the stage B) mixture is from 50 to 97% by weight, C) cooling of the resultant blend, where no polyols are added in stages A) to C), and where the total index of the thermoplastic polyurethane is from 1.0 to 1.2. A) reaction of at least one thermoplastic polyurethane with at least one diisocyanate or one isocyanate prepolymer which has at least two isocyanate groups, or a mixture thereof, in the melt, with reduction of the molar mass of the thermoplastic polyurethane and with formation of a thermoplastic polyurethane having an excess of isocyanate end groups, B) introduction of at least one polylactide into the melt of the stage A) product, and reaction of the stage A) product with the polylactide at a temperature below 190°C, where the proportion of the polylactide in the stage B) mixture is from 50 to 97% by weight, C) cooling of the resultant blend,
A process for producing a blister strip for a dry powder inhaler, the blister strip comprising a base material having blister cavities , the process comprising: • dosing a first formulation of medicament (A) into a first set of blister cavities; • sealing a first lid material to the first set of cavities; and subsequently • dosing a second, different formulation of medicament (B) into a second set of cavities; • sealing a second, separate lid material to the second set of cavities. • dosing a first formulation of medicament (A) into a first set of blister cavities; • sealing a first lid material to the first set of cavities; and subsequently • dosing a second, different formulation of medicament (B) into a second set of cavities; • sealing a second, separate lid material to the second set of cavities.
An electrolytic capacitor-specific electrode member for an electrolytic capacitor, the electrolytic capacitor-specific electrode member having a wire shape, the electrolytic capacitor-specific electrode member having an outer surface including: at least one first cavity portions opened to outside; and at least one second cavity portions opened at least to the at least one first cavity portions , the at least one second cavity portions being smaller in opening diameter represented by a circle equivalent diameter than the at least one first cavity portions , characterised in that the depth of the at least one first cavity portions is 0.5 μm to 250 μm. the electrolytic capacitor-specific electrode member having a wire shape, the electrolytic capacitor-specific electrode member having an outer surface including: at least one first cavity portions opened to outside; and at least one second cavity portions opened at least to the at least one first cavity portions , at least one first cavity portions opened to outside; and at least one second cavity portions opened at least to the at least one first cavity portions , the at least one second cavity portions being smaller in opening diameter represented by a circle equivalent diameter than the at least one first cavity portions , characterised in that the depth of the at least one first cavity portions is 0.5 μm to 250 μm.
Hybrid scaffold suitable for regenerating animal tissues characterized in that it comprises: - peripheral layers made of materials suitable for interfacing with the tissues at the implant site and integrating with the host body cells; - one or more intermediate layers made of combined materials which together are suitable for giving the scaffold mechanical properties suited to withstand the typical stresses in the implantation site and for generating stable coalescence between the layers, the materials being: - fibroin for the peripheral layers, - polyurethane combined with fibroin for each intermediate layer. - peripheral layers made of materials suitable for interfacing with the tissues at the implant site and integrating with the host body cells; - one or more intermediate layers made of combined materials which together are suitable for giving the scaffold mechanical properties suited to withstand the typical stresses in the implantation site and for generating stable coalescence between the layers, - fibroin for the peripheral layers, - polyurethane combined with fibroin for each intermediate layer.
A pharmaceutical composition for use in reducing a risk of one or more of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, and unstable angina, in a subject on statin therapy, wherein the subject has a fasting baseline triglyceride level of 135 mg/dl to 500 mg/dl and diabetes mellitus and is aged 50 years or older, and at least one of: (a) is a male age 55 or older or a female age 65 or older; (b) is a cigarette smoker or was a cigarette smoker who stopped less than 3 months prior; (c) has hypertension; (d) has an HDL-C level of ≤ 40 mg/dL for men or ≤ 50 mg/dL for women; (e) has an hs-CRP level of > 3.0 mg/L; (f) has renal dysfunction; (g) has retinopathy; (h) has microalbuminuria; (i) has macroalbuminuria; and/or (j) has an ankle-brachial index of < 0.9 without symptoms of intermittent claudication, wherein the pharmaceutical composition comprises 4 g of eicosapentaenoic acid ethyl ester, administered to the subject per day, and wherein the eicosapentaenoic acid ethyl ester comprises at least 96 wt.% of all omega-3 fatty acids in the pharmaceutical composition. wherein the subject has a fasting baseline triglyceride level of 135 mg/dl to 500 mg/dl and diabetes mellitus and is aged 50 years or older, and at least one of: (a) is a male age 55 or older or a female age 65 or older; (b) is a cigarette smoker or was a cigarette smoker who stopped less than 3 months prior; (c) has hypertension; (d) has an HDL-C level of ≤ 40 mg/dL for men or ≤ 50 mg/dL for women; (e) has an hs-CRP level of > 3.0 mg/L; (f) has renal dysfunction; (g) has retinopathy; (h) has microalbuminuria; (i) has macroalbuminuria; and/or (j) has an ankle-brachial index of < 0.9 without symptoms of intermittent claudication, wherein the pharmaceutical composition comprises 4 g of eicosapentaenoic acid ethyl ester, administered to the subject per day, and wherein the eicosapentaenoic acid ethyl ester comprises at least 96 wt.% of all omega-3 fatty acids in the pharmaceutical composition.
An arithmetic logic unit, ALU , including: a pre-processing unit operable to receive N ∗ 2 pixels at horizontal coordinates [X, X+N ∗ 2) and to generate therefrom N overlapping windows of N pixels, with N pixels being N words, as first data, the N overlapping windows being from horizontal coordinates [X+j, X+F+j) where j = 0 to N-1; a first routing grid connected to a plurality of N data lanes, wherein the first routing grid is adapted to drive each of the windows to a corresponding data lane ; a second routing grid connected to the data lanes , wherein the second routing grid is adapted to feed the same N filter coefficients as second data into all the data lanes ; wherein each of the data lanes include a plurality of N functional units with first inputs from the first routing grid and second inputs from the second routing grid wherein the functional units are operable to compute N instances of a multiplication function of the respective first data and the respective second data outputting N results having K' bits per word; wherein each of the data lanes include a reduction unit with inputs from the functional units , wherein the reduction unit is configured to perform a bit reduction operation to reduce the number of bits from N ∗ K' to J' where J' < N ∗ K', the reduction unit being configured so that the results are added to an accumulator, the accumulator being configured to provide a data lane output of J' bits; wherein the ALU is configured to process the N windows in parallel in the data lanes. a pre-processing unit operable to receive N ∗ 2 pixels at horizontal coordinates [X, X+N ∗ 2) and to generate therefrom N overlapping windows of N pixels, with N pixels being N words, as first data, the N overlapping windows being from horizontal coordinates [X+j, X+F+j) where j = 0 to N-1; a first routing grid connected to a plurality of N data lanes, wherein the first routing grid is adapted to drive each of the windows to a corresponding data lane ; a second routing grid connected to the data lanes , wherein the second routing grid is adapted to feed the same N filter coefficients as second data into all the data lanes ; wherein each of the data lanes include a plurality of N functional units with first inputs from the first routing grid and second inputs from the second routing grid wherein the functional units are operable to compute N instances of a multiplication function of the respective first data and the respective second data outputting N results having K' bits per word; wherein each of the data lanes include a reduction unit with inputs from the functional units , wherein the reduction unit is configured to perform a bit reduction operation to reduce the number of bits from N ∗ K' to J' where J' < N ∗ K', the reduction unit being configured so that the results are added to an accumulator, the accumulator being configured to provide a data lane output of J' bits; wherein the ALU is configured to process the N windows in parallel in the data lanes.
A compound of formula I, A is a isoxazolyl or triazolyl; B is a pyrazinyl, pyrimidinyl or pyridinyl; R 1 is methyl; R 2 is methyl; R 3 is selected from the group consisting of i) hydrogen, ii) C 3-6 -cycloalkyl, iii) halogen-C 1-6 -alkyl, and iv) C 1-6 -alkyl; R 4 is selected from the group consisting of i) hydrogen, and ii) C 1-6 -alkyl; R 5 is selected from the group consisting of i) C 1-6 -alkyl, and ii) halogen-C 1-6 -alkyl; R 6 is F; R 7 is selected from the group consisting of i) amino, ii) cyano, iii) hydrogen, iv) OH, v) halogen, vi) C 1-6 -alkyl, vii) C 1-6 -alkyl-C 3-6 -cycloalkyl, viii) halogen-C 1-6 -alkyl, ix) C 1-6 -alkoxy-C 1-6 -alkyl, x) C 2-6 -alkynyl, xi) C 2-6 -alkynyl-C 1-6 -alkyl, xii) C 2-6 -alkynyl-C 1-6 -alkoxy xiii) C 1-6 -alkoxy, and xiv) halogen-C 1-6 -alkoxy; or pharmaceutically acceptable salts thereof. A is a isoxazolyl or triazolyl; B is a pyrazinyl, pyrimidinyl or pyridinyl; R 1 is methyl; R 2 is methyl; R 3 is selected from the group consisting of i) hydrogen, ii) C 3-6 -cycloalkyl, iii) halogen-C 1-6 -alkyl, and iv) C 1-6 -alkyl; i) hydrogen, ii) C 3-6 -cycloalkyl, iii) halogen-C 1-6 -alkyl, and iv) C 1-6 -alkyl; R 4 is selected from the group consisting of i) hydrogen, and ii) C 1-6 -alkyl; i) hydrogen, and ii) C 1-6 -alkyl; R 5 is selected from the group consisting of i) C 1-6 -alkyl, and ii) halogen-C 1-6 -alkyl; i) C 1-6 -alkyl, and ii) halogen-C 1-6 -alkyl; R 6 is F; R 7 is selected from the group consisting of i) amino, ii) cyano, iii) hydrogen, iv) OH, v) halogen, vi) C 1-6 -alkyl, vii) C 1-6 -alkyl-C 3-6 -cycloalkyl, viii) halogen-C 1-6 -alkyl, ix) C 1-6 -alkoxy-C 1-6 -alkyl, x) C 2-6 -alkynyl, xi) C 2-6 -alkynyl-C 1-6 -alkyl, xii) C 2-6 -alkynyl-C 1-6 -alkoxy xiii) C 1-6 -alkoxy, and xiv) halogen-C 1-6 -alkoxy; i) amino, ii) cyano, iii) hydrogen, iv) OH, v) halogen, vi) C 1-6 -alkyl, vii) C 1-6 -alkyl-C 3-6 -cycloalkyl, viii) halogen-C 1-6 -alkyl, ix) C 1-6 -alkoxy-C 1-6 -alkyl, x) C 2-6 -alkynyl, xi) C 2-6 -alkynyl-C 1-6 -alkyl, xii) C 2-6 -alkynyl-C 1-6 -alkoxy xiii) C 1-6 -alkoxy, and xiv) halogen-C 1-6 -alkoxy;
A protection switching method, wherein a protection group comprises a first protection switching node and a second protection switching node, and at least two transmission paths between the first protection switching node and the second protection switching node, the method comprises: obtaining , by the first protection switching node, a final path bandwidth combination when monitoring that bandwidth of at least one transmission path in the protection group changes, wherein the final path bandwidth combination includes bandwidths of the at least two transmission paths after the bandwidth of the at least one transmission path changes; querying , by the first protection switching node, a stored mapping relationship between a path bandwidth combination and a channel allocation policy according to the final path bandwidth combination, and determining the channel allocation policy on a path corresponding to the final path bandwidth combination; updating, by the first protection switching node, an initial channel allocation policy to the channel allocation policy on the path corresponding to the final path bandwidth combination; and performing , by the first protection switching node, channel switching according to the channel allocation policy corresponding to the final path bandwidth combination. obtaining , by the first protection switching node, a final path bandwidth combination when monitoring that bandwidth of at least one transmission path in the protection group changes, wherein the final path bandwidth combination includes bandwidths of the at least two transmission paths after the bandwidth of the at least one transmission path changes; querying , by the first protection switching node, a stored mapping relationship between a path bandwidth combination and a channel allocation policy according to the final path bandwidth combination, and determining the channel allocation policy on a path corresponding to the final path bandwidth combination; updating, by the first protection switching node, an initial channel allocation policy to the channel allocation policy on the path corresponding to the final path bandwidth combination; and performing , by the first protection switching node, channel switching according to the channel allocation policy corresponding to the final path bandwidth combination.
An implantable vestibular prosthesis system for mechanically stimulating sensory epithelium in a vestibular system using an opto-acoustic effect arising from optical stimulation comprising: an implantable optical array including a plurality of optical sources configured for engagement with a disordered vestibular system to deliver optical stimulation signals to target optical stimulation locations within the bony or membranous labyrinth of the disordered vestibular system; and an implantable stimulation processor connected to the optical array and configured for carrying out an optical signal generating process controlling the optical sources to produce the optical stimulation signals as sequences of optical pulses to produce the optical stimulation signals with the optical sources so as to generate directional pressure waves within the endolymphatic fluid directed to target stimulation locations for vestibular perception by residual vestibular functioning. an implantable optical array including a plurality of optical sources configured for engagement with a disordered vestibular system to deliver optical stimulation signals to target optical stimulation locations within the bony or membranous labyrinth of the disordered vestibular system; and an implantable stimulation processor connected to the optical array and configured for carrying out an optical signal generating process controlling the optical sources to produce the optical stimulation signals as sequences of optical pulses to produce the optical stimulation signals with the optical sources so as to generate directional pressure waves within the endolymphatic fluid directed to target stimulation locations for vestibular perception by residual vestibular functioning.